This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calvo-Calle, J. M.
Right arrow Articles by Nardin, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calvo-Calle, J. M.
Right arrow Articles by Nardin, E. H.

 Previous Article  |  Next Article 

Infection and Immunity, December 2006, p. 6929-6939, Vol. 74, No. 12
0019-9567/06/$08.00+0     doi:10.1128/IAI.01151-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

A Linear Peptide Containing Minimal T- and B-Cell Epitopes of Plasmodium falciparum Circumsporozoite Protein Elicits Protection against Transgenic Sporozoite Challenge{triangledown}

J. Mauricio Calvo-Calle,1,{dagger} Giane A. Oliveira,1,{ddagger} Carol Othoro Watta,1 Jonathan Soverow,1 Carlos Parra-Lopez,2 and Elizabeth H. Nardin1*

Department of Medical Parasitology, New York University School of Medicine, New York, New York,1 Fundacion Instituto de Inmunologia de Colombia, Grupo Functional Inmuologia, Bogota, Colombia2

Received 22 July 2006/ Returned for modification 27 August 2006/ Accepted 26 September 2006

An effective malaria vaccine is needed to address the public health tragedy resulting from the high levels of morbidity and mortality caused by Plasmodium parasites. The first protective immune mechanism identified in the irradiated sporozoite vaccine, the "gold standard" for malaria preerythrocytic vaccines, was sporozoite-neutralizing antibody specific for the repeat region of the surface circumsporozoite (CS) protein. Previous phase I studies demonstrated that a branched peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum CS protein elicited antirepeat antibody and CD4+-T-cell responses comparable to those observed in volunteers immunized with irradiated P. falciparum sporozoites. The current study compares the immunogenicity of linear versus tetrabranched peptides containing the same minimal T- and B-cell epitopes, T1BT*, comprised of a CS-derived universal Th epitope (T*) synthesized in tandem with the T1 and B repeats of P. falciparum CS protein. A simple 48-mer linear synthetic peptide was found to elicit antisporozoite antibody and gamma interferon-secreting T-cell responses comparable to the more complex tetrabranched peptides in inbred strains of mice. The linear peptide was also immunogenic in outbred nonhuman primates (Aotus nancymaae), eliciting antibody titers equivalent to those induced by tetrabranched peptides. Importantly, the 48-mer linear peptide administered in adjuvants suitable for human use elicited antibody-mediated protection against challenge with rodent malaria transgenic sporozoites expressing P. falciparum CS repeats. These findings support further evaluation of linear peptides as economical, safe, and readily produced malaria vaccines for the one-third of the world's population at risk of malaria infection.

* Corresponding author. Mailing address: Department of Medical Parasitology, New York University School of Medicine, 341 East 25th Street, New York, NY 10010. Phone: (212) 263-6819. Fax: (212) 263-8116. E-mail: nardie01{at}med.nyu.edu.

{triangledown} Published ahead of print on 9 October 2006.

Editor: W. A. Petri, Jr.

{dagger} Present address: Department of Pathology, University of Massachusetts School of Medicine, 55 Lake Avenue North, Worcester, MA 01655.

{ddagger} Present address: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591.

Infection and Immunity, December 2006, p. 6929-6939, Vol. 74, No. 12
0019-9567/06/$08.00+0     doi:10.1128/IAI.01151-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Othoro, C., Johnston, D., Lee, R., Soverow, J., Bystryn, J.-C., Nardin, E. (2009). Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod. Infect. Immun. 77: 739-748 [Abstract] [Full Text]  
  • Mlambo, G., Kumar, N. (2008). Transgenic Rodent Plasmodium berghei Parasites as Tools for Assessment of Functional Immunogenicity and Optimization of Human Malaria Vaccines. Eukaryot Cell 7: 1875-1879 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»